VolitionRx reports Q1 revenue $0.25M, consensus $1.08M

Cash and cash equivalents as of March 31, 2025 totaled approximately $2.6M vs. $3.3M as of December 31, 2024. “2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q platform in the human diagnostics market. I am delighted to report we are in confidential discussions with more than ten companies. Notably, the combined market value of seven of these companies exceeds $600billion, underscoring the significant global strength, potential reach and impact our technology could achieve through such partnerships. Our goal is to secure multiple licensing agreements in the human diagnostics space this year, mirroring our successful strategy in the veterinary market, with diverse deal structures, all with ongoing revenue and some to include milestone payments. The second prong of our Nu.Q NETs commercial strategy is to leverage our granted CE mark, approved in the EU for any NETs related diseases. I am delighted to report that we have reached a significant commercial milestone, in that we recorded our first revenue from sales of our CE-marked Nu.Q NETs automated product in Europe in 1Q 25. This is the first revenue we have generated from a regulated, clinically approved product.”